Magnus Ingelman-Sundberg

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 38

Top Topics

Clinical Decision Support

Top Venues

Clinical pharmacology and therapeutics

Hepatology communications

Clinical and translational science

This page only lists publications with an associated author ORCID identifier.

Publications

Robert Løvsletten Smith, Birgit M Wollmann, Elisabet Størset, Hasan Çağın Lenk, Kevin Sean O'Connell, Marianne Kristiansen Kringen, Magnus Ingelman-Sundberg, Espen Molden
Effect of the NFIB rs28379954 T>C polymorphism on CYP2D6-catalyzed metabolism of solanidine. Clinical and translational science 17 (2) (2024)
Sander van Riet, Anais Julien, Andrea Atanasov, Åsa Nordling, Magnus Ingelman-Sundberg
The role of sinusoidal endothelial cells and TIMP1 in the regulation of fibrosis in a novel human liver 3D NASH model. Hepatology communications 8 (3) (2024)
Robert Løvsletten Smith, Birgit M Wollmann, Elisabet Størset, Hasan Çağın Lenk, Kevin Sean O'Connell, Marianne Kristiansen Kringen, Magnus Ingelman-Sundberg, Espen Molden
Effect of the NFIB rs28379954 T>C polymorphism on CYP2D6-catalyzed metabolism of solanidine. Clinical and translational science 17 (2) (2024)
Magnus Ingelman-Sundberg, Volker Martin Lauschke
Individualized Pharmacotherapy Utilizing Genetic Biomarkers and Novel In Vitro Systems As Predictive Tools for Optimal Drug Development and Treatment. Drug metabolism and disposition: the biological fate of chemicals 52 (6) (2024)
Sander van Riet, Anais Julien, Andrea Atanasov, Åsa Nordling, Magnus Ingelman-Sundberg
The role of sinusoidal endothelial cells and TIMP1 in the regulation of fibrosis in a novel human liver 3D NASH model. Hepatology communications 8 (3) (2024)
Sander van Riet, Anais Julien, Andrea Atanasov, Åsa Nordling, Magnus Ingelman-Sundberg
The role of sinusoidal endothelial cells and TIMP1 in the regulation of fibrosis in a novel human liver 3D NASH model. Hepatology communications 8 (3) (2024)
Magnus Ingelman-Sundberg, Munir Pirmohamed
Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment. Journal of internal medicine (2024)
Sander van Riet, Anais Julien, Andrea Atanasov, Åsa Nordling, Magnus Ingelman-Sundberg
The role of sinusoidal endothelial cells and TIMP1 in the regulation of fibrosis in a novel human liver 3D NASH model. Hepatology communications 8 (3) (2024)
Magnus Ingelman-Sundberg, Volker Martin Lauschke
Individualized pharmacotherapy utilizing genetic biomarkers and novel in vitro systems as predictive tools for optimal drug development and treatment . Drug metabolism and disposition: the biological fate of chemicals (2024)
Magnus Ingelman-Sundberg, Espen Molden
Therapeutic drug monitoring, liquid biopsies or pharmacogenomics for prediction of human drug metabolism and response. British journal of clinical pharmacology (2024)
Sander van Riet, Anais Julien, Andrea Atanasov, Åsa Nordling, Magnus Ingelman-Sundberg
The role of sinusoidal endothelial cells and TIMP1 in the regulation of fibrosis in a novel human liver 3D NASH model. Hepatology communications 8 (3) (2024)
Magnus Ingelman-Sundberg, Munir Pirmohamed
Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment. Journal of internal medicine 295 (5) (2024)
Magnus Ingelman-Sundberg, Volker Martin Lauschke
Individualized Pharmacotherapy Utilizing Genetic Biomarkers and Novel In Vitro Systems As Predictive Tools for Optimal Drug Development and Treatment. Drug metabolism and disposition: the biological fate of chemicals 52 (6) (2024)
Magnus Ingelman-Sundberg, Munir Pirmohamed
Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment. Journal of internal medicine 295 (5) (2024)
Robert Løvsletten Smith, Birgit M Wollmann, Elisabet Størset, Hasan Çağın Lenk, Kevin Sean O'Connell, Marianne Kristiansen Kringen, Magnus Ingelman-Sundberg, Espen Molden
Effect of the NFIB rs28379954 T>C polymorphism on CYP2D6-catalyzed metabolism of solanidine. Clinical and translational science 17 (2) (2024)
Magnus Ingelman-Sundberg
Pharmacogenomic Prescribing Guidelines: Are They Always Useful? Clinical pharmacology and therapeutics (2024)
Sara Redenšek Trampuž, Sander van Riet, Åsa Nordling, Magnus Ingelman-Sundberg
The Role of CTGF in Liver Fibrosis Induced in 3D Human Liver Spheroids. Cells 12 (2) (2023)
Magnus Ingelman-Sundberg, Marin M Jukić, Line Skute Bråten, Marianne Kristiansen Kringen, Espen Molden
What is the Current Clinical Impact of the CYP2CTG Haplotype? Clinical pharmacology and therapeutics (2023)
Sara Redenšek Trampuž, Sander van Riet, Åsa Nordling, Magnus Ingelman-Sundberg
The Role of CTGF in Liver Fibrosis Induced in 3D Human Liver Spheroids. Cells 12 (2) (2023)
Sara Redenšek Trampuž, Sander van Riet, Åsa Nordling, Magnus Ingelman-Sundberg
The Role of CTGF in Liver Fibrosis Induced in 3D Human Liver Spheroids. Cells 12 (2) (2023)
Sara Redenšek Trampuž, Sander van Riet, Åsa Nordling, Magnus Ingelman-Sundberg
The Role of CTGF in Liver Fibrosis Induced in 3D Human Liver Spheroids. Cells 12 (2) (2023)
Sara Redenšek Trampuž, Sander van Riet, Åsa Nordling, Magnus Ingelman-Sundberg
The Role of CTGF in Liver Fibrosis Induced in 3D Human Liver Spheroids. Cells 12 (2) (2023)
Katharina Klöditz, Eida Tewolde, Åsa Nordling, Magnus Ingelman-Sundberg
Mechanistic, functional and clinical aspects of pro-inflammatory cytokine mediated regulation of ADME gene expression in 3D human liver spheroids. Clinical pharmacology and therapeutics (2023)
Erkka Järvinen, Helen S Hammer, Oliver Pötz, Magnus Ingelman-Sundberg, Tore Bjerregaard Stage
3D Spheroid Primary Human Hepatocytes for Prediction of Cytochrome P450 and Drug Transporter Induction. Clinical pharmacology and therapeutics (2023)
Birgit M Wollmann, Robert Løvsletten Smith, Marianne Kristiansen Kringen, Magnus Ingelman-Sundberg, Espen Molden, Elisabet Størset
Evidence for solanidine as a dietary CYP2D6 biomarker: Significant correlation with risperidone metabolism. British journal of clinical pharmacology (2023)
Hasan Çağın Lenk, Robert Løvsletten Smith, Kevin Sean O'Connell, Marin M Jukić, Marianne Kristiansen Kringen, Ole Andreas Andreassen, Magnus Ingelman-Sundberg, Espen Molden
Impact of NFIB and CYP1A variants on clozapine serum concentration-A retrospective naturalistic cohort study on 526 patients with known smoking habits. Clinical and translational science (2022)
Chris S Pridgeon, Inger Johansson, Magnus Ingelman-Sundberg
Liquid Biopsies or Therapeutic Drug Monitoring for CYP Activity Profile Determination. Clinical pharmacology and therapeutics 112 (5) (2022)
Chris S Pridgeon, Inger Johansson, Magnus Ingelman-Sundberg
Response to Rowland et al. and Achour et al. Clinical pharmacology and therapeutics 112 (6) (2022)
Hasan Çağın Lenk, Katharina Klöditz, Inger Johansson, Robert Løvsletten Smith, Marin M Jukić, Espen Molden, Magnus Ingelman-Sundberg
The Polymorphic Nuclear Factor NFIB Regulates Hepatic CYP2D6 Expression and Influences Risperidone Metabolism in Psychiatric Patients. Clinical pharmacology and therapeutics 111 (5) (2022)
Magnus Ingelman-Sundberg
The missing heritability in pharmacogenomics: role of NFIB and other factors. Pharmacogenomics 23 (8) (2022)
Chris S Pridgeon, Dian P Bolhuis, Filip Milosavljević, Marina Manojlović, Ákos Végvári, Massimiliano Gaetani, Marin M Jukić, Magnus Ingelman-Sundberg
Hepatocyte Thorns, A Novel Drug-Induced Stress Response in Human and Mouse Liver Spheroids. Cells 11 (10) (2022)
Sigrid Haeggström, Magnus Ingelman-Sundberg, Svante Pääbo, Hugo Zeberg
The clinically relevant CYP2C8*3 and CYP2C9*2 haplotype is inherited from Neandertals. The pharmacogenomics journal 22 (4) (2022)
Volker Martin Lauschke, Magnus Ingelman-Sundberg
Emerging strategies to bridge the gap between pharmacogenomic research and its clinical implementation. NPJ genomic medicine 5 (2020)
Cathelijne H van der Wouden, Mandy H van Rhenen, Wafa O M Jama, Magnus Ingelman-Sundberg, Volker Martin Lauschke, Lidija Konta, Matthias Schwab, Jesse Joachim Swen, Henk-Jan Guchelaar
Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing. Clinical pharmacology and therapeutics 106 (4) (2019)
Richard J Weaver, Eric A Blomme, Amy E Chadwick, Ian M Copple, Helga H J Gerets, Christopher E Goldring, Andre Guillouzo, Philip G Hewitt, Magnus Ingelman-Sundberg, Klaus Gjervig Jensen, Satu Juhila, Ursula Klingmüller, Gilles Labbe, Michael J Liguori, Cerys A Lovatt, Paul Morgan, Dean J Naisbitt, Raymond H H Pieters, Jan Snoeys, Bob van de Water, Dominic P Williams, B Kevin Park
Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. Nature reviews. Drug discovery 19 (2) (2019)
Line Skute Bråten, Tore Haslemo, Marin M Jukic, Magnus Ingelman-Sundberg, Espen Molden, Marianne K Kringen
Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 45 (3) (2019)
Sebastian Prill, Andrea Caddeo, Guido Baselli, Oveis Jamialahmadi, Paola Dongiovanni, Raffaela Rametta, Kajsa P Kanebratt, Arturo Pujia, Piero Pingitore, Rosellina Margherita Mancina, Daniel Lindén, Carl Whatling, Annika Janefeldt, Mikael Kozyra, Magnus Ingelman-Sundberg, Luca Valenti, Tommy B Andersson, Stefano Romeo
The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. Scientific reports 9 (1) (2019)
Mikael Kozyra, Inger Johansson, Åsa Nordling, Shahid Ullah, Volker Martin Lauschke, Magnus Ingelman-Sundberg
Human hepatic 3D spheroids as a model for steatosis and insulin resistance. Scientific reports 8 (1) (2018)